Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Surgical Results of Growth Hormone-Secreting Pituitary Adenoma

  • Kim, Min-Su (Department of Neurosurgery, Yeungnam University College of Medicine) ;
  • Jang, Hyun-Dong (Department of Neurosurgery, Yeungnam University College of Medicine) ;
  • Kim, Oh-Lyong (Department of Neurosurgery, Yeungnam University College of Medicine)
  • Published : 2009.05.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission. Methods: Forty-two patients with GH-secreting pituitary adenoma underwent transsphenoidal surgery (TSS) between 1995 and 2007. The patient group included 23 women and 19 men, with a mean age of 40.2 (range 13-61) years, and a mean follow-up duration of 49.4 (range 3-178) months after the operation. For comparable radiological criteria, we classified parasellar growth into five grades according to the Knosp classification. We analyzed the surgical results of the patients according to the most recent stringent criteria for cure. Results: The overall rate of endocrinological remission in the group of 42 patients after primary TSS was 64% (26 of 42). The remission rate was 67% (8 of 12) for microadenoma and 60% (18 of 30) for macroadenoma. The remission rate was 30%(3 of 10) for the group with cavernous sinus invasion and 72% (23 of 32) for the group with intact cavernous sinus. Cavernous sinus invasion in Knosp grade III and IV was significantly correlated with the remission rate. There was a significant relationship between preoperative mean GH concentration and early postoperative outcome, with most patients in remission having a lower preoperative GH concentration. Conclusion: TSS is thought to be an effective primary treatment for GH-secreting pituitary adenomas according to the most recent criteria of cure. Because the remission rate in cases with cavernous sinus invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly.

Keywords

References

  1. Abbassioun K, Amirjamshidi M, Mehrazin A, Khalatbary I, Keynama M, Bokai H, et al : A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon : a follow-up of more than 23 years. Surg Neurol 66 : 26-31; discussion 31, 2006 https://doi.org/10.1016/j.surneu.2005.11.063
  2. Beauregard C, Truong U, Hardy J, Serri O : Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58 : 86-91, 2003 https://doi.org/10.1046/j.1365-2265.2003.01679.x
  3. Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, et al : A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol Lett 27 : 828-832, 2006
  4. Bush ZM, Vance ML : Management of acromegaly : is there a role for primary medical therapy? Rev Endocr Metab Disord 9 : 83-94, 2008 https://doi.org/10.1007/s11154-007-9061-1
  5. Carmichael JD, Bonert VS : Medical therapy : options and uses. Rev Endocr Metab Disord 9 : 71-81, 2008 https://doi.org/10.1007/s11154-007-9068-7
  6. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC : Assessment of disease activity in treated acromegalic patients using a sensitive GH assay : should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87 : 3142-3147, 2002 https://doi.org/10.1210/jc.87.7.3142
  7. De P, Rees DA, Davies N, John R, Neal J, Mills RG, et al : Transsphenoidal surgery for acromegaly in wales : results based on stringent criteria of remission. J Clin Endocrinol Metab 88 : 3567-3572, 2003 https://doi.org/10.1210/jc.2002-021822
  8. Eastman RC, Gorden P, Glatstein E, Roth J : Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 21 : 693-712, 1992
  9. Fukuoka S, Ito T, Takanashi M, Hojo A, Nakamura H : Gamma knife radiosurgery for growth hormone-secreting pituitary adenomas invading the cavernous sinus. Stereotact Funct Neurosurg 76 : 213-217, 2001 https://doi.org/10.1159/000066721
  10. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al : Criteria for cure of acromegaly : a consensus statement. J Clin Endocrinol Metab 85 : 526-529, 2000 https://doi.org/10.1210/jc.85.2.526
  11. Goffman TE, Dewan R, Arakaki R, Gorden P, Oldfield EH, Glatstein E : Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safety of postsurgical radiation therapy. Cancer 69 : 271-275, 1992 https://doi.org/10.1002/1097-0142(19920101)69:1<271::AID-CNCR2820690145>3.0.CO;2-U
  12. Isono M, Inoue R, Kamida T, Kobayashi H, Matsuyama J : Significance of leptin expression in invasive potential of pituitary adenomas. Clin Neurol Neurosurg 105 : 111-116, 2003 https://doi.org/10.1016/S0303-8467(02)00129-4
  13. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T : Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136 : 37-43, 1995 https://doi.org/10.1007/BF01411433
  14. Kim IM, Yim MB, Lee CY : The outcome of transsphenoidal microsurgery for acromegaly. J Korean Neurosurg Soc 32 : 131-135, 2002
  15. Knosp E, Steiner E, Kitz K, Matula C : Pituitary adenomas with invasion of the cavernous sinus space : a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 : 610-617; discussion 617-618, 1993 https://doi.org/10.1227/00006123-199310000-00008
  16. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr : Surgical management of GH-secreting pituitary adenomas : an outcome study using modern remission criteria. J Clin Endocrinol Metab 86 : 4072-4077, 2001 https://doi.org/10.1210/jc.86.9.4072
  17. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al : Stereotactic radiosurgery for recurrent surgically treated acromegaly : comparison with fractionated radiotherapy. J Neurosurg 88 : 1002-1008, 1998 https://doi.org/10.3171/jns.1998.88.6.1002
  18. Ludecke DK, Abe T : Transsphenoidal microsurgery for newly diagnosed acromegaly : a personal view after more than 1,000 operations. Neuroendocrinology 83 : 230-239, 2006 https://doi.org/10.1159/000095533
  19. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G : Evolving criteria for post-operative biochemical remission of acromegaly : can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 10 : 611-619, 2003 https://doi.org/10.1677/erc.0.0100611
  20. Newman CB : Medical therapy for acromegaly. Endocrinol Metab Clin North Am 28 : 171-190, 1999 https://doi.org/10.1016/S0889-8529(05)70062-1
  21. Nomikos P, Buchfelder M, Fahlbusch R : The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152 : 379-387, 2005 https://doi.org/10.1530/eje.1.01863
  22. Orme SM, McNally RJ, Cartwright RA, Belchetz PE : Mortality and cancer incidence in acromegaly : a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83 :2730-2734, 1998 https://doi.org/10.1210/jc.83.8.2730
  23. Petrovich Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML : Gamma knife radiosurgery for pituitary adenoma : early results. Neurosurgery 53 : 51-59; discussion 59-61, 2003 https://doi.org/10.1227/01.NEU.0000068702.00330.47
  24. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK : Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41 : 95-102, 1994 https://doi.org/10.1111/j.1365-2265.1994.tb03789.x
  25. Shimon I, Cohen ZR, Ram Z, Hadani M : Transsphenoidal surgery for acromegaly : endocrinological follow-up of 98 patients. Neurosurgery 48 : 1239-1243; discussion 1244-1245, 2001 https://doi.org/10.1097/00006123-200106000-00008
  26. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al : Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83 : 3419-3426, 1998 https://doi.org/10.1210/jc.83.10.3419
  27. Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, et al : Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg 98 : 1084-1093, 2003 https://doi.org/10.3171/jns.2003.98.5.1084
  28. Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW : Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 93 (Suppl 3) : 6-9, 2000

Cited by

  1. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas vol.29, pp.4, 2010, https://doi.org/10.3171/2010.7.focus10153
  2. Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas vol.97, pp.5, 2009, https://doi.org/10.1177/030089161109700517
  3. Acromegaly surgery in Manchester revisited – The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission vol.76, pp.3, 2012, https://doi.org/10.1111/j.1365-2265.2011.04193.x
  4. Medical Therapy of Acromegaly vol.2012, pp.None, 2012, https://doi.org/10.1155/2012/268957
  5. Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: patient and tumor characteristics evaluated by magnetic resonance imaging vol.16, pp.2, 2013, https://doi.org/10.1007/s11102-012-0395-7
  6. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission vol.16, pp.4, 2009, https://doi.org/10.1007/s11102-012-0440-6
  7. Aggressive tumors and difficult choices in acromegaly vol.17, pp.suppl1, 2009, https://doi.org/10.1007/s11102-013-0538-5
  8. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification vol.122, pp.4, 2015, https://doi.org/10.3171/2014.12.jns141083
  9. Endoscopic versus microscopic approach for surgical treatment of acromegaly vol.38, pp.3, 2009, https://doi.org/10.1007/s10143-015-0613-7
  10. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center vol.51, pp.3, 2009, https://doi.org/10.1007/s12020-015-0619-5
  11. A magnetic resonance imaging‐based classification system for indication of trans‐sphenoidal hypophysectomy in canine pituitary‐dependent hypercortisolism vol.57, pp.5, 2009, https://doi.org/10.1111/jsap.12474
  12. The surgical treatment of acromegaly vol.20, pp.1, 2009, https://doi.org/10.1007/s11102-016-0765-7
  13. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis vol.39, pp.5, 2017, https://doi.org/10.1080/01616412.2017.1296653
  14. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature vol.129, pp.2, 2018, https://doi.org/10.3171/2017.2.jns162673
  15. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature vol.129, pp.2, 2018, https://doi.org/10.3171/2017.2.jns162673
  16. Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review vol.23, pp.5, 2009, https://doi.org/10.1007/s11102-020-01063-x